Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
1. The overall objective response rate was 35.1% in patients with initial measurable disease, all of which were partial responses, ...
Tag: adagrasib
#VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. Median progression-free survival was 5.6 ...
Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
1. Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. 2. Median progression-free survival ...